U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.15 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.10 (+0.14%)
     
  • Gold

    1,802.10
    +0.30 (+0.02%)
     
  • Silver

    25.24
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1774
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3757
    -0.0011 (-0.08%)
     
  • USD/JPY

    110.5120
    +0.3970 (+0.36%)
     
  • BTC-USD

    34,497.67
    +388.79 (+1.14%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Myriad Genetics, Inc.’s MYGN GeneSight pharmacogenomics test was recently rolled out with Integrated Prescription Management (IPM), a pharmacy benefits management (PBM) company. Notably, the IPM will now provide pharmacogenomics testing for people suffering from depression or anxiety.

For investors’ note, IPM was founded in 2009 and offers high-touch service, insightful analytics, and strategic cost-management solutions.

The recent development is expected to help Myriad Genetics expand its customer base, thereby boosting its Molecular Diagnostic testing business.

GeneSight Test at a Glance

The GeneSight test from Myriad Genetics enables clinicians and patients to better understand a particular individual’s response to certain medications.

Notably, GeneSight is a psychotropic test that evaluates how a patient’s genes impact, how they may break down or respond to certain medications that are usually prescribed to treat depression, anxiety, and other psychiatric conditions.

With a simple cheek swab, clinicians will now understand which medications may require dose adjustments, might be less likely to work or have a high risk of side effects based on a person's genetic composition.

More on the News

It is noteworthy to mention that in the United States, anxiety and depression are the most common mental health disorders with above 18% of adults suffering from anxiety and around 8% having experienced a depressive episode.

Zacks Investment Research
Zacks Investment Research

Considering the facts, GeneSight pharmacogenomics will become a game-changing employee benefit. The innovative technology might do away with weeks of taking a prescription that doesn't work. This will save people’s time and improve productivity.

Progress in GeneSight Test

In the first quarter of 2021, Myriad Genetics’ GeneSight test volume rose 17% sequentially. Further, GeneSight test saw a strong increase in new ordering providers, with more than 2,600 physicians ordering GeneSight for the first time in the quarter. Overall, the number of ordering physicians increased 10% sequentially and test utilization per provider rose 4% sequentially.

In February 2021, Myriad Genetics announced the publication of a new analysis regarding its GeneSight psychotropic test in the peer-reviewed journal Psychiatry Research. The analysis demonstrates that the combinatorial approach available in the GeneSight test is better than single-gene testing for predicting patient outcomes and medication blood levels.

Industry Prospects

Per a report by EMERGEN RESEARCH, the global pharmacogenomics market size was valued at $6.16 billion in 2019 and is expected to reach $11.97 billion by 2027, at a CAGR of 8.7%. Rising prevalence of chronic ailments and demand for personalized therapy are factors driving the market.

Price Performance

Shares of the company have gained 88.6% in a year’s time against the industry’s fall of 7.9%.

Zacks Rank and Key Picks

Currently, the company carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are National Vision Holdings, Inc. EYE, The Cooper Companies, Inc. COO and Envista Holdings Corporation NVST. While National Vision sports a Zacks Rank #1 (Strong Buy), both The Cooper Companies and Envista Holdings carry a Zacks Rank #2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.

National Vision has a projected long-term earnings growth rate of 23%.

The Cooper Companies has a projected long-term earnings growth rate of 11%.

Envista Holdings has an estimated long-term earnings growth rate of 26%.

Zacks' Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Cooper Companies, Inc. (COO) : Free Stock Analysis Report

Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report

National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report

Envista Holdings Corporation (NVST) : Free Stock Analysis Report

To read this article on Zacks.com click here.